This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Linder, J. Articles by Weisenburger, D. D. Search for Related Content PubMed PubMed Citation Articles by Linder, J. Articles by Weisenburger, D. D.

American Journal of Pathology, Vol 127, 1-8, Copyright © 1987 by American Society for Investigative Pathology

REGULAR ARTICLES

Monoclonal antibodies marking T lymphocytes in paraffin-embedded tissue

J Linder, YL Ye, DS Harrington, JO Armitage and DD Weisenburger

The authors investigated the ability of 70 monoclonal antibodies obtained from the Third International Workshop on Human Leukocyte Antigens (Oxford, 1986) to mark T lymphocytes in B5-fixed paraffin- embedded tissue. No staining occurred with 65 of the antibodies; however, 5 antibodies marked small lymphocytes in the T-cell areas of human tonsil. Two antibodies which strongly labeled lymphocytes, UCHL1 and T2/48, were used to examine 106 cases of non-Hodgkin's lymphoma, 29 cases of Hodgkin's disease, and a variety of normal and neoplastic tissues. UCHL1 and T2/48 each marked 86% (37/43) of B5-fixed T-cell lymphomas. Only 50% of formalin-fixed T-cell lymphomas were marked with these antibodies. UCHL1 marked 1.8% (1/56) of the B-cell lymphomas, compared with T2/48, which marked 19.6% (11/56) of the B-cell lymphomas. T2/48 had the interesting attribute of marking cells of the follicular mantle-zone and intermediate lymphocytic lymphoma, suggesting that the antibody recognizes a B-cell differentiation antigen. No Reed-Sternberg cells, epithelial neoplasms, sarcomas, neurogenic tumors, or normal nonlymphoid tissue were marked by either antibody. These antibodies successfully mark T cells in paraffin tissue sections and should aid in the investigation and characterization of abnormal lymphoid proliferations, "undifferentiated" malignant neoplasms, and immunologically mediated disorders.

This article has been cited by other articles:

				F. Millot, S. Suciu, N. Philippe, Y. Benoit, F. Mazingue, A. Uyttebroeck, P. Lutz, F. Mechinaud, A. Robert, P. Boutard, et al. Value of High-Dose Cytarabine During Interval Therapy of a Berlin-Frankfurt-Munster-Based Protocol in Increased-Risk Children With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Results of the European Organization for Research and Treatment of Cancer 58881 Randomized Phase III Trial J. Clin. Oncol., April 1, 2001; 19(7): 1935 - 1942. [Abstract] [Full Text] [PDF]

				B Maes, R Achten, A Demunter, B Peeters, G Verhoef, and C De Wolf-Peeters Evaluation of B cell lymphoid infiltrates in bone marrow biopsies by morphology, immunohistochemistry, and molecular analysis J. Clin. Pathol., November 1, 2000; 53(11): 835 - 840. [Abstract] [Full Text] [PDF]

				J. S. Sidhu, R. Rigotti, and P. Schotanus Primary Adenoidal Hodgkin's Disease: Report of a Case with an Unusual Morphology and Review of the Literature International Journal of Surgical Pathology, July 1, 2000; 8(3): 241 - 246. [Abstract] [PDF]

				F. Facchetti, J. K. C. Chan, W. Zhang, A. Tironi, M. Chilosi, S. Parolini, L. D. Notarangelo, and L. E. Samelson Linker for Activation of T Cells (LAT), a Novel Immunohistochemical Marker for T Cells, NK Cells, Mast Cells, and Megakaryocytes : Evaluation in Normal and Pathological Conditions Am. J. Pathol., April 1, 1999; 154(4): 1037 - 1046. [Abstract] [Full Text] [PDF]

				F. Millot, A. Robert, Y. Bertrand, F. Mechinaud, G. Laureys, A. Ferster, P. Brock, P. Rohrlich, F. Mazingue, D. Plantaz, et al. Cutaneous Involvement in Children With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Pediatrics, July 1, 1997; 100(1): 60 - 64. [Abstract] [Full Text] [PDF]